/
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, …
The business is unprofitable at the operating level (-60.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 13.4% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$27M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$7M
▼ -13.4% YoY
Net Income (TTM)
-$21M
▲ +82.5% YoY
Op. Margin
-100.17%
▲ +347.8pp YoY
ROIC
-56.33%
▲ +118.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▲ +31.2% YoY
Op. Cash Flow (TTM)
-$29M
▲ +31.2% YoY
Net Debt
-$14M
Net Cash Position
Cash & Equiv.
$15M
5Y CAGR: -2.7%
Continue Research